.Attribute Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after an average consequence of 11 months, clients along with metastatic gastrointestinal growths who obtained biomarker-matched therapies based on circulating cyst DNA profiling showed a greater clinical benefit than those receiving incomparable therapy.